Development of docking-based 3D-QSAR models for PPARgamma full agonists

Journal of Molecular Graphics and Modelling

Volumn 36, Issue , 2012, Pages 1-9

  Guasch, Laura ^a   Sala, Esther ^a   Valls, Cristina ^a   Mulero, Miquel ^a   Pujadas, Gerard ^a,b   Garcia Vallvé, Santiago ^a,b  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^b TECNIO   (Spain)

Author keywords

3D QSAR; Antidiabetics; Drug design; PPARgamma agonists; Protein ligand docking

Indexed keywords

3D-QSAR; ANTIDIABETICS; DRUG DESIGN; PPARGAMMA AGONISTS; PROTEIN-LIGAND DOCKING;

AMINO ACIDS; BINDING ENERGY; COMPUTATIONAL CHEMISTRY; CYTOLOGY; DERMATOLOGY; MOLECULAR GRAPHICS;

THREE DIMENSIONAL;

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; TYROSINE DERIVATIVE;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG CONFORMATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; MOLECULAR DOCKING; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; THREE DIMENSIONAL QUANTITATIVE STRUCTURE ACTIVITY RELATION; TRANSACTIVATION;

HUMANS; HYPOGLYCEMIC AGENTS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PPAR GAMMA; PROTEIN BINDING; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84861125438     PISSN: 10933263     EISSN: 18734243     Source Type: Journal    
DOI: 10.1016/j.jmgm.2012.03.001     Document Type: Article

References (25)

1. A. Yessoufou, and W. Wahli Multifaceted roles of peroxisome proliferator-activated receptors (PPARs) at the cellular and whole organism levels Swiss Med. Wkly. 140 2010 w13071
2. S. Garcia-Vallve, and J. Palau Nuclear receptors, nuclear-receptor factors, and nuclear-receptor-like orphans form a large paralog cluster in Homo sapiens Mol. Biol. Evol. 15 1998 665 682 (Pubitemid 28240672)
3. J. Berger, and D.E. Moller The mechanisms of action of PPARs Annu. Rev. Med. 53 2002 409 435 (Pubitemid 34177889)
4. T.M. Willson, M.H. Lambert, and S.A. Kliewer Peroxisome proliferator-activated receptor gamma and metabolic disease Annu. Rev. Biochem. 70 2001 341 367 (Pubitemid 32662214)
5. J.M. Lehmann, L.B. Moore, T.A. Smith-Oliver, W.O. Wilkison, T.M. Willson, and S.A. Kliewer An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma) J. Biol. Chem. 270 1995 12953 12956
6. L. Michalik, and W. Wahli Peroxisome proliferator-activated receptors (PPARs) in skin health, repair and disease Biochim. Biophys. Acta 1771 2007 991 998 (Pubitemid 47198543)
7. P. Sertznig, M. Seifert, W. Tilgen, and J. Reichrath Peroxisome proliferator-activated receptors (PPARs) and the human skin: importance of PPARs in skin physiology and dermatologic diseases Am. J. Clin. Dermatol. 9 2008 15 31 (Pubitemid 351993189)
8. R. Behshad, K.D. Cooper, and N.J. Korman A retrospective case series review of the peroxisome proliferator-activated receptor ligand rosiglitazone in the treatment of atopic dermatitis Arch. Dermatol. 144 2008 84 88 (Pubitemid 351159393)
9. D. Schadendorf Peroxisome proliferator-activating receptors: a new way to treat melanoma? J. Invest. Dermatol. 129 2009 1061 1063
10. B.R. Henke, S.G. Blanchard, M.F. Brackeen, K.K. Brown, J.E. Cobb, J.L. Collins, W.W. Harrington, M.A. Hashim, E.A. Hull-Ryde, I. Kaldor, S.A. Kliewer, D.H. Lake, L.M. Leesnitzer, J.M. Lehmann, J.M. Lenhard, L.A. Orband-Miller, J.F. Miller, R.A. Mook, S.A. Noble, W. Oliver, D.J. Parks, K.D. Plunket, J.R. Szewczyk, and T.M. Willson N-(2-benzoylphenyl)-l-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents J. Med. Chem. 41 1998 5020 5036 (Pubitemid 28555461)
11. J.L. Collins, S.G. Blanchard, G.E. Boswell, P.S. Charifson, J.E. Cobb, B.R. Henke, E.A. Hull-Ryde, W.M. Kazmierski, D.H. Lake, L.M. Leesnitzer, J. Lehmann, J.M. Lenhard, L.A. Orband-Miller, Y. Gray-Nunez, D.J. Parks, K.D. Plunkett, and W.Q. Tong N-(2-benzoylphenyl)-l-tyrosine PPARgamma agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety J. Med. Chem. 41 1998 5037 5054 (Pubitemid 28555462)
12. J.E. Cobb, S.G. Blanchard, E.G. Boswell, K.K. Brown, P.S. Charifson, J.P. Cooper, J.L. Collins, M. Dezube, B.R. Henke, E.A. Hull-Ryde, D.H. Lake, J.M. Lenhard, W. Oliver, J. Oplinger, M. Pentti, D.J. Parks, K.D. Plunket, and W.Q. Tong N-(2-benzoylphenyl)-l-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent J. Med. Chem. 41 1998 5055 5069 (Pubitemid 28555463)
13. S. Azukizawa, M. Kasai, K. Takahashi, T. Miike, K. Kunishiro, M. Kanda, C. Mukai, and H. Shirahase Synthesis and biological evaluation of (S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids: a novel series of PPAR gamma agonists Chem. Pharm. Bull. (Tokyo) 56 2008 335 345 (Pubitemid 351463247)
14. J. Rudolph, L. Chen, D. Majumdar, W.H. Bullock, M. Burns, T. Claus, F.E. Dela Cruz, M. Daly, F.J. Ehrgott, J.S. Johnson, J.N. Livingston, R.W. Schoenleber, J. Shapiro, L. Yang, M. Tsutsumi, and X. Ma Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR alpha/gamma/delta pan agonists: synthesis, structure-activity relationship, and in vivo efficacy J. Med. Chem. 50 2007 984 1000 (Pubitemid 46394001)
15. R.T. Gampe, V.G. Montana, M.H. Lambert, A.B. Miller, R.K. Bledsoe, M.V. Milburn, S.A. Kliewer, T.M. Willson, and H.E. Xu Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors Mol. Cell 5 2000 545 555
16. V. Zoete, A. Grosdidier, and O. Michielin Peroxisome proliferator- activated receptor structures: ligand specificity, molecular switch and interactions with regulators Biochim. Biophys. Acta 1771 2007 915 925 (Pubitemid 47208545)
17. L. Guasch, E. Sala, C. Valls, M. Blay, M. Mulero, L. Arola, G. Pujadas, and S. Garcia-Vallve Structural insights for the design of new PPARgamma partial agonists with high binding affinity and low transactivation activity J. Comput. Aided Mol. Des. 25 2011 717 728
18. C. Giaginis, S. Theocharis, and T.K. Anna A QSAR Study on indole-based PPARg agonists in respect to receptor binding and gene transactivation data QSAR Comb. Sci. 28 2009 802 805
19. L. Rathi, S.K. Kashaw, A. Dixit, G. Pandey, and A.K. Saxena Pharmacophore identification and 3D-QSAR studies in N-(2-benzoyl phenyl)-l-tyrosines as PPAR gamma agonists Bioorg. Med. Chem. 12 2004 63 69 (Pubitemid 38096218)
20. C. Liao, A. Xie, L. Shi, J. Zhou, and X. Lu Eigenvalue analysis of peroxisome proliferator-activated receptor gamma agonists J. Chem. Inf. Comput. Sci. 44 2004 230 238
21. K.H. Hyun, D.Y. Lee, B. Lee, and C.K. Kim Receptor-based 3D QSAR studies on PPAR-gamma agonists using CoMFA and CoMSIA approaches QSAR Comb. Sci. 23 2004 637 649 (Pubitemid 39531950)
22. Y. Kurogi Three-dimensional quantitative structure-activity relationships (3D-QSAR) of antidiabetic thiazolidinediones Drug Des. Discov. 16 1999 109 118 (Pubitemid 29450339)
23. M. Kapoor, M. McCann, S. Liu, K. Huh, C.P. Denton, D.J. Abraham, and A. Leask Loss of peroxisome proliferator-activated receptor gamma in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis Arthritis Rheum. 60 2009 2822 2829
24. C. Rücker, M. Scarsi, and M. Meringer 2D QSAR of PPARgamma agonist binding and transactivation Bioorg. Med. Chem. 14 2006 5178 5195 (Pubitemid 43903265)
25. S.L. Dixon, A.M. Smondyrev, E.H. Knoll, S.N. Rao, D.E. Shaw, and R.A. Friesner PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results J. Comput. Aided Mol. Des. 20 2006 647 671 (Pubitemid 46023928)